RxDoctor Payments Data

Anas Gremida, MD

Gastroenterology · Saint Louis, MONPI 1295098457

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $789 of the $1,038 with a category attached, or 76.0%. 7 manufacturers reported payments, led by AbbVie at 55.4% of the total. That places this record below the midpoint for gastroenterology clinicians in MO, where the typical reported total is $1,415.

$1,038in general payments, 2019–2025

Across 46 payments — averaging $22.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$576
  • Takeda Pharmaceuticals U.S.A., Inc.$198
  • Gilead$85
  • Johnson & Johnson$84
  • Sandoz$67
  • Ironwood Pharmaceuticals, Inc$15
  • plus $14 from 1 others
$197,214in research payments, 2019–2025

Across 73 payments — averaging $2701.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$165K
  • Hoffmann-la Roche Limited$20K
  • F. Hoffmann-la Roche AG$12K

What the payments were for

  • Speaking & faculty fees$989%
  • Food & beverage$78976%
  • Education$15115%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,038 in reported general payments places this provider in the 45th percentile of 374 gastroenterology providers in Missouri.

See all gastroenterology providers in Missouri

Medicare billing

Part B allowed, 2024
$48,771
Medicare patients
229
Services billed
359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab40$1,093,651
Humira(Cf) PenAdalimumab13$88,984
Mesalamine67$34,592
Mesalamine ErMesalamine17$5,016
Azathioprine45$3,229
Mercaptopurine24$2,234
Budesonide DrBudesonide22$1,903
LoperamideLoperamide Hcl23$1,688
Colestipol Hcl13$1,437
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl105$1,296
Sulfasalazine20$800
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine32$780
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl22$354
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl21$349
Omeprazole23$235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$84$1,093,65140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 374 gastroenterology providers in Missouri.

Other gastroenterology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →